… The discovery of the role of the RAS/RAF/MEK/ERK pathway … inhibitor approved for therapy
of advanced melanomas … toxicity of the combination therapy compared to vemurafenib. …

… Clinical studies using combination therapy in the … viable melanoma cells, reduced proliferation
of residual melanoma cells, and increased apoptosis after 14 days of dabrafenib therapy, …

… not only led to acquired resistance to BRAF inhibitors, but also conferred resistance to MEK
inhibitors, suggesting that combination therapy slows down but does not prevent … carried out …

… In melanoma cells that harbour BRAF V600 mutation (one of the major kinases in the
RAS-RAF-MEK-ERK pathway), … of combined therapy after failure of BRAF inhibitor monotherapy. …

… melanoma treatment. Here, we present a recompilation of the combined therapies clinically
… The latest type-I inhibitor approved for the treatment of metastatic melanoma is encorafenib (…

… New treatment strategies that target key effectors of the RAF/MEK/ERK pathway may display
… Evidence suggests that inhibition of a single effector involved in melanoma pathogenesis …

… that the oncogenic signal promoted by mutant BRAF inhibition is countered by MEK1/2
inhibition. This finding further supports the use of combination therapy over monotherapy. …

… In melanoma, the RAS/RAF/MEK/ERK mitogen-activated … The activity of MEK inhibition with
binimetinib in NRAS-mutated … on combination treatments for NRAS-mutated melanoma are …

… as well as to combination therapy with BRAFi and MEKi [66]. … of new inhibitors of the
RAF/MEK/ERK signaling axis is the … -mutated melanoma cells suppress DC function, but that this …

… of a MEK inhibitor alleviated the side effects by inhibiting the … a period of treatment with
BRAF/MEK combination therapy. … of treatment with UI-152 (an inhibitor of BRAF) in melanoma …